section name header

Introduction

Essentials of Diagnosis
  • Heart rate greater than 100 bpm.

  • Rhythm is supraventricular in origin.

General Considerations

Supraventricular tachycardias (SVTs) are rapid rhythm disturbances originating from the atria or the atrioventricular (AV) node. In the absence of a bundle branch block, there is intact conduction to the ventricles via the right and left bundles leading to a narrow and normal-appearing QRS. Therefore, these arrhythmias are also often called narrow complex tachycardias. Because many of the SVTs are episodic, many clinicians also refer to this group of arrhythmias as paroxysmal SVTs. Radiofrequency ablation has become an important therapeutic option in the management of SVTs because of its ability to cure these arrhythmias safely. Table 111 outlines the pharmacologic therapy for SVTs.

Table 111. Antiarrhythmic Drugs for Supraventricular Tachycardias

AgentIndicationIntravenous DoseOral DoseAdverse EffectsDrug Interactions
Class Ia
QuinidineAF, AFL, AVNRT, AVRT610 mg/kg over 2030 min200400 mg q46h; q8h with long-acting preparationsHypotension (especially IV), ventricular proarrhythmia, GI disturbance, thrombocytopenia

Digitalis level

Warfarin effect

Metoprolol, propranolol, propafenone levels

ProcainamideAF, AFL, AVNRT, AVRT

Bolus: 15 mg/kg given as 20 mg/min

Infusion: 24 mg/min

50 mg/kg/day q34h; twice daily dosage with longacting preparationGI disturbance, hypotension, SLE, agranulocytosis, FUO hemolytic anemia, myasthenia gravis aggravation, ventricular proarrhythmiaProcainamide level with cimetidine, quinidine, and amiodarone
Class Ic
FlecainideAF, AFL, AT, AVNRT, AVRTN/A50200 mg q12hVentricular proarrhythmia, CHF, GI disturbance, CNS (dizziness, tremor, light-headedness)

Digitalis level

Flecainide level with amiodarone, cimetidine, Norpace, propranolol

Flecainide level with smoking

PropafenoneAF, AFL, AVNRT, AVRTN/A150300 mg q8h or 225425 mg bid (long-acting form)GI disturbance, CNS (dizziness), metallic taste, CHF, first-degree AVB, IVCD, positive ANASynergism with β-blockers
Class II (IV)
EsmololVentricular rate control for AF, AFL, ST, AT

Bolus: 500 mcg/kg over 12 min

Infusion: 50200 mcg/kg/min

N/ACHF, AVB, bradycardia, bronchospasm
PropranololVentricular rate control for AF, AFL, ST, AT15 mg at 1 mg/min20320 mg/day q6h, q8h, q12h, or once daily, depending on preparationCHF, AVB, bradycardia, bronchospasm
Class III
SotalolAF, AFL, AVNRT, AVRT, ATN/A80160 mg q12hDyspnea, fatigue, dizziness, CHF, bradycardia, ventricular proarrhythmia, bronchospasmSynergism with Ca2+ antagonists or β-blockers
AmiodaroneAF, AFL, AVNRT, AVRT, AT

Bolus: 150 mg over 10 min

Infusion: 1 mg/min × 6 h, then 0.5 mg/min

100400 mg once dailyPulmonary toxicity, CHF, tremor, bradycardia, LFTs, corneal deposits, skin discoloration, GI intolerance, hyper-/hypothyroidism

Digoxin levels

Warfarin effect

Quinidine, procainamide/NAPA, flecainide

Phenytoin level

IbutilideAF, AFL1 mg bolus over 10 min; second bolus, if needed, after 10-min waitN/AVentricular proarrhythmia, hypotension, GI disturbance
DofetilideAF, AFLN/A125500 mcg twice daily modified by algorithmVentricular proarrhythmia, headache, chest pain, nausea, dizzinessContraindicated with verapamil, cimetidine, ketoconazole, trimethoprim
Class IV
DiltiazemAF, AFL, AVNRT, AVRT, AT, MAT

Bolus: 0.25 mg/min over 2 min then 0.35 mg/kg in 15 min if needed

Infusion: 515 mg/h

90360 mg/day in 14 divided doses, depending on preparationHypotension, bradycardia, CHF, AVBSynergism with β-blockers
VerapamilAF, AFL, AVNRT, AVRT, AT, MAT2.520 mg over 20 min in divided doses40120 mg q8h; 240360 mg once daily of longacting preparationHypotension, bradycardia, CHF, AVBSynergism with β-blockers
Class V
AdenosineSVT diagnosis, AVNRT, AVRT, AT termination6 mg IV rapid bolus followed by 12 mg × 2 if needed; half dosage if administered in central lineN/AChest tightness, facial flushing, dyspnea, AVB

Activity by dipyridamole

Activity by theophylline

DigoxinVentricular rate control for AF, AFL, AT (generally not very effective in active patients)Up to 1.0 mg bolus in divided doses followed by 0.1250.375 mg/day0.1250.375 mg/day in single doseGI disturbance, conduction defects, atrial/ventricular arrhythmias, headache, visual disturbances

Digoxin level: amiodarone, quinidine, verapamil, indomethacin, spironolactone, alprazolam, erythromycin, tetracycline

Digoxin level: antacids, cholestyramine, rifampin, neomycin

Risk of digitalis toxicity with potassium-depleting diuretics

AF, atrial fibrillation; AFL, atrial flutter; ANA, antinuclear antigen; AT, atrial tachycardia; AVB, atrioventricular block; AVNRT, atrioventricular nodal reentrant tachycardia; AVRT, atrioventricular reciprocating tachycardia; CHF, congestive heart failure; CNS, central nervous system; FUO, fever of unknown origin; GI, gastrointestinal; IV, intravenous; IVCD, intraventricular conduction delay; LFT, liver function tests; MAT, multifocal atrial tachycardia; N/A, not applicable; NAPA, N-acetyl procainamide; SLE, systemic lupus erythematosus; ST, sinus tachycardia.

Pathophysiology/Etiology

Tachyarrhythmias occur as a result of three main mechanisms: reentry, which is most common; enhanced or abnormal automaticity; and triggered activity.

Reentrant arrhythmias sustain themselves by repetitively following a revolving pathway comprising two limbs, one that takes the impulse away from and one that carries it back to the site of origin. For reentry to exist, an area of slow conduction must occur, and each limb must have a different refractory period (see the discussion on AV nodal reentrant tachycardia). In this situation, ectopic beats or pacing (by inducing refractoriness in one limb of the circuit) can initiate a reentrant tachycardia. Once established, ectopic beats or pacing can also terminate the tachycardia by interfering with impulse propagation in one of the limbs.

The second mechanism, automaticity, refers to spontaneous and, often, repetitive firing from a single focus, which may either be ectopic or may originate in the sinus node. This mechanism comprises two subcategories. Enhanced automaticity is defined as a focus that fires spontaneously and may originate in the sinus node, subsidiary pacemakers in the atrium including the Eustachian ridge, Bachmann bundle, coronary sinus and AV valves, the AV node, His-Purkinje system, and the ventricles. Abnormal automaticity is usually secondary to a disease process causing alterations in ionic flow that produces a less negative resting diastolic membrane potential. Threshold potential is therefore more easily attained, thereby increasing the probability of a sustained arrhythmia.

The third mechanism, triggered arrhythmias, depends on oscillations in the membrane potential that closely follow an action potential. In the absence of a new external electrical stimulus, these oscillations, or after-depolarizations, cause new action potentials to develop. Thus, each new action potential results from the previous action potential. These arrhythmias can be produced by early or late after-depolarization, depending on the timing of the first after-depolarization relative to the preceding action potential (the one that spawned the triggered activity). In early after-depolarizations, membrane repolarization is incomplete, which allows an action potential to be initiated by a subthreshold stimulus. This type is often associated with electrolyte disturbance and may be the mechanism responsible for arrhythmogenesis related to the prolonged QT syndrome and torsades de pointes caused by quinidine. With delayed after-depolarization, membrane repolarization is complete, but an abnormal intracellular calcium load causes spontaneous depolarization. The high calcium levels can be related to the inhibition of the sodium pump by drugs such as digoxin. In either type of arrhythmia, the process may be repetitive and lead to a sustained tachycardia.

General Diagnostic Approach

A systematic approach to interpreting the 12-lead electrocardiogram (ECG) will allow accurate determination of the type of SVT in most cases (Figure 111). The first step is to determine whether the rhythm is regular or irregular. If it is irregular, the rhythm is likely either atrial fibrillation, atrial flutter with variable conduction, or multifocal atrial tachycardia (MAT). The appearance of the P waves or lack of P waves will usually distinguish between these three entities. In atrial fibrillation, there is chaotic atrial activity. In atrial flutter, P waves are seen at a rate of 240320 bpm. In MAT, there are P waves preceding each QRS complex, and there are at least three different P-wave morphologies.

Figure 11-1. Algorithm for distinguishing supraventricular tachycardias. AF, atrial fibrillation; AFL, atrial flutter; AT, atrial tachycardia; AVNRT, atrioventricular nodal reentrant tachycardia; AVRT, atrioventricular reciprocating tachycardia; JT, junctional tachycardia; MAT, multifocal atrial tachycardia; SN, sinus node; ST, sinus tachycardia; SVT, supraventricular tachycardia.

If the SVT is regular, there are several main types of SVT to consider. The SVT could be sinus tachycardia, sinus node reentry, atrial flutter, atrial tachycardia, AV nodal reentrant tachycardia (AVNRT), junctional tachycardia, or atrioventricular reciprocating tachycardia (AVRT). The type of regular SVT can be usually identified by examining four aspects of the 12-lead ECG: onset and termination, heart rate, P-wave morphology, and R-P relationship. Sinus tachycardia and junctional tachycardia typically have very gradual onset, whereas the other SVTs usually start and stop more suddenly. Rate can also be helpful since sinus tachycardia cannot typically go over 220 bpm minus age, and the heart rate in atrial flutter is often a multiple of 300. P-wave morphology can be helpful because retrograde P waves (negative in the inferior leads: II, III, and aVF) favor AVNRT and junctional tachycardia. Finally, R-P relationship refers to the distance from the R wave to the next P wave during tachycardia. If this distance is longer than the P-R interval, the SVT is termed “long R-P,” whereas if this distance is short, it is termed “short R-P” (Figure 112).

Figure 11-2. Short R-P refers to a regular supraventricular tachycardia (SVT) where the R-P interval is shorter than the P-R interval. Long R-P refers to a regular SVT where the R-P interval is longer than the P-R interval.